FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA OKs Neuralstem IND for Anti-depressant

[ Price : $8.95]

FDA approves a Neuralstem, Inc. IND to begin a Phase 1a safety trial of NSI-189 in major depression.

FDA, Pfizer Faulted on Chantix Trials

[ Price : $8.95]

The investigative journalism Web site Fairwarning criticizes FDA and Pfizer for not initially testing Chantix on patients with men...

FDA Clears Radiosurgery Component for Lung Cancer

[ Price : $8.95]

FDA clears an Accuray Inc. 510(k) for its Lung Optimized Treatment, a new component for the firm's CyberKnife VSI System for perfo...

Orion Mulls Lawsuit to Block Generic Comtan

[ Price : $8.95]

Orion Corp. considers a patent infringement suit against Mylan after being told the company has submitted an ANDA for a generic co...

Guidance on Co-Developing Two Combo Drugs

[ Price : $8.95]

Federal Register Notice: FDA releases a draft guidance on the co-development of two or more unmarketed investigational drugs for u...

New Offices Added to Tobacco Center

[ Price : $8.95]

Federal Register Notice: FDA adds two new offices to its Center for Tobacco Products.

Pros and Cons of Mercury Amalgam Presented to FDA Panel

[ Price : $8.95]

FDAs Medical Devices Advisory Committee hears a wide variety of views regarding the safety and classification of dental amalgam.

Safety Board Discusses Methemoglobinemia, Benzocaine

[ Price : $8.95]

CDERs Drug Safety Oversight Board says it discussed a concern involving benzocaine and methemglobinemia at its 11/18 meeting.

Adventrx Wants FDA Meeting on ANX-514 Study

[ Price : $8.95]

Adventrx Pharmaceuticals says it is seeking a meeting with FDA to discuss results of a bioquivalence study of its drug candidate A...

FDA Concerned About Some Dietary Supplement Ingredients

[ Price : $8.95]

FDA tells dietary supplement manufacturers it is concerned about products containing undeclared or deceptively-labeled ingredients...